GELS

Strong Annual Results Driven by Record-Setting Revenues for Fifth Quarter in a Row, Setting Stage for Another Record Year in 2026   LAS VEGAS, NV / ACCESS Newswire / April 2, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported preliminary unaudited results for year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted. 2025 Financial Highlights 2025 net revenue is expected to increase 45% to a record $4.5 million, with the increase due to the merger with Gummy USA, continued technological innovation, product line and distribution channel expansion, and strengthening direct-to-consumer and retail sales. Existing operations generated net revenue growth of approximately 25%. Direct-to-consumer product subscriptions increased 47% and Amazon "Subscribe & Save" customers increased 36% in 2025. Subscription customer growth continued to expand the company's recurring revenue stream and increase customer lifetime value while enhancing customer communications and retention. 2025 Operational Highlights At the beginning of the fourth quarter, completed the strategic merger with Florida-based Gummy USA™, a leading developer and advanced manufacturer of precision-dosed nutraceutical gummies. The merger added Gummy USA's HACCP, GMP-certified and FDA-registered manufacturing facility expanded Healthy Extracts' vertical integration of R&D, outsourced manufacturing, marketing and distribution. Combined with Healthy Extracts' existing exclusive delivery systems (gel-packs and functional drinking straws), Gummy USA has unlocked a third specialized product development and marketing channel comprised of precision-dosed gummies for the nutraceutical and pharmaceutical markets. The Gummy USA Florida manufacturing facility and in-house R&D has begun to accelerate Healthy Extracts' overall product development and manufacturing process, enhance gross margins, and substantially strengthen the company's IP portfolio. Don Swanson, seasoned entrepreneur and manufacturing engineer and Gummy USA founder, was appointed CEO and chairman of Healthy Extracts. He further strengthened the management team as a recognized innovator in the fast-growing $13 billion global gummy supplement market. He invented and developed advanced, patent-pending white-label and private-label m...

Gelteq (GELS) announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company’s proprietary oral gel platform. The findings demonstrate that Gelteq’s platform significantly enhances the absorption and bioavailability of cannabidiol compared to an existing FDA approved oil-based product. Despite having a much lower concentration of CBD, Gelteq’s formulation achieved greater than 22% increase in bioavailability along with a higher peak exposure. As such, the results demonstrate that our oral gel platform enhances the delivery of lipophilic cannabinoid molecules and delivers more efficient uptake in the body. These results create a clear pathway for a potential expedited market launch of new medicinal cannabis products in Australia via the Special Access Scheme which could position Gelteq for efficient entry into additional global markets. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GELS: Disclaimer & DisclosureReport an Issue Gelteq announces new partnership with Hong Kong Flag Football Program Gelteq Limited Unveils Innovative Drug Delivery Platform in Investor Summit Gelteq entered into three year sales agreement with Mana Health Gelteq announces preclinical findings from study of gel-based platform Gelteq announces ‘positive’ preclinical results for its gel formulation

MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company’s proprietary oral gel platform. The findings demonstrate that Gelteq’s platform significantly enhances the absorption and bioavailability of cannabidiol (“CBD”) compared to an existing FDA approved oil-based product. The preliminary results reinforces our platform’s potential to change how medicinal cannabis is delivered and experienced by patients. Despite having a much lower concentration of CBD, Gelteq’s formulation achieved greater than 22% increase in bioavailability along with a higher peak exposure. As such, the results demonstrate that our oral gel platform enhances the delivery of lipophilic cannabinoid molecules and delivers more efficient uptake in the body. These results create a clear pathway for a potential expedited market launch of new medicinal cannabis products in Australia via the Special Access Scheme (“SAS”) which could position Gelteq for efficient entry into additional global markets. The SAS is an Australian Government program that allows authorised healthcare practitioners to prescribe medicinal cannabis products to patients without the products undergoing the full Therapeutic Goods Administration (“TGA”) approval process. As a resault, the SAS could potentially grant our oral gel platform earlier patient access and a faster pathway to market. A Major Advancement for Medicinal Cannabis Patients These results represent a meaningful step forward for patients who rely on medicinal cannabis, extracts or cannabinoids for therapeutic outcomes. Traditional products such as CBD oils and vapes often present challenges which include variable dosing, slow onset, inconsistent absorption, unpleasant taste, and inhalation-related risks. Gelteq’s oral gel platform overcomes these limitations by offering a safer, predictable and more convenient alternative. As Gelteq’s oral gel platform improves bioavailability, patients may achieve therapeutic effects with lower doses which could reduce exposure to unnecessary excipients or cannabinoids. The oral gel format enables pre-measured and precise dosing with no use of droppers and...

Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug Classes MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced positive preclinical results showing its proprietary gel formulation achieved substantially higher bioavailability than a leading on-market reference antihistamine product. In a comparative pharmacokinetic study, Gelteq’s formulation demonstrated a 38–45% increase in systemic exposure and absorption (AUC) and markedly higher peak concentrations (Cmax), while maintaining a comparable time to peak plasma concentration (Tmax). The results of the study show Gelteq’s gel-based delivery technology can significantly enhance oral bioavailability of the drug, in addition to the broad benefits of the technology in solving drug delivery, swallowing and patient compliance issues. “These results represent a major technical and commercial milestone for Gelteq,” said Nathan Givoni, CEO of Gelteq. “A 38–45% improvement in bioavailability is transformative and validates our platform’s ability to meaningfully enhance the performance of established drugs. These results also position Gelteq to pursue a much broader portfolio of pharmaceutical opportunities where similar outcomes can be achieved via our proprietary gel-based delivery technology.” Importantly, the findings extend beyond the specific antihistamine evaluated in the study. Because the test compound is water-soluble, the demonstrated bioavailability improvement provides a strong foundation for applying Gelteq’s platform across a range of other water-soluble drug classes, significantly broadening the Company’s commercial scope. “These results support our strategy of partnering and developing gel-based formulations across a wide range of therapeutically relevant compounds,” Mr. Givoni added. “We believe this opens up opportunities well beyond the antihistamine market, and into much larger drug categories where improved absorption, ease of administration, and patient-friendly formats can create immediate value.” The Company anticipates using these results to further pursue an FDA approval pathway for an antihistamine product and to increase engagement with potential pharmaceutical partners interested in next-generation dr...

Hydrate EZ™ delivers rapid hydration and essential electrolytes for staying refreshed, sharp and in control. Mynus Sugar™ is clinically formulated to support healthy carbohydrate metabolism. Both products feature exclusive oral delivery technology in a flavorful, super-convenient, 2-oz. gel pack format-no water or mixing required. Proprietary gel manufacturing process complements company's new exclusive SureDose™ gummy manufacturing and functional drinking straw technologies. LAS VEGAS, NV / ACCESS Newswire / September 4, 2025 / Healthy Extracts™ Inc. (OTCQB:HYEX), a platform for acquiring, developing, manufacturing and marketing science-based nutraceuticals for brain, heart, and metabolic health, has officially launch to the North American market two new breakthrough performance and wellness products featuring Gelteq's (NASDAQ:GELS) proprietary gel-based delivery system: Hydrate EZ™ and Mynus Sugar™. Designed for today's on-the-go lifestyle, Hydrate EZ™ delivers great tasting rapid hydration and essential electrolytes in a convenient 2-oz. gel pack format with twist-off cap. The no-mix, no-mess electrolyte gel is designed to keep you hydrated, energized, and balanced without sugar or caffeine. Whether you're working out, working in the yard, or just working, Hydrate EZ helps you stay focused, refreshed and in control. The great tasting Mynus Sugar™ gel-pack is a clinically formulated supplement that supports healthy post-meal carbohydrate metabolism. It is designed to reduce the amount of sugar absorbed into the bloodstream after eating carbohydrates. Like with Hydrate EZ, no water or mixing is required, just easy-to-take-along soft gel-packs that you can throw in your backpack, purse or glovebox and consume on-the-go, anytime, anywhere. Both products are the first of their kind to enter the North American nutraceutical market based on Gelteq's advanced consumable gel technology. They will be marketed and distributed by Healthy Extracts' BergametNA™, building off the subsidiary's market leadership in heart health and brain performance. The new products are available for purchase today from Bergametna.com and from the BergametNA Amazon Store. Purchases of any heart or sleep product from BergametNA.com will receive free samples of Hydrate EZ™ and Mynus Sugar™. Save an additional 20% when signing up for Subscribe & Save at Bergametna.com or e...